Biopharma thought leadership

Artificial intelligence driving inventory management for improved single-use systems manufacturing

Artificial Intelligence offers a new smart technological approach to reducing the complexity of the single use component library supply chain. Learn how predictive forecasting based on real time usage, with positive feedback to the original manufacturer drives anticipative demand.

Advancing mRNA vaccine production management

Across the biopharma industry, manufacturers of mRNA vaccines and therapeutics are seeking new tools and resources to help improve the safety, stability and quality of their mRNA drug products. Read about two key resources that can support scale-up production.

Industry perspective: Scale up challenges for cell & gene therapy manufacturers

Dr. Ger Brophy, EVP Biopharma Production, provides insights into manufacturing challenges, including scale up, mitigating raw material shortages and supply chain issues, and other industry trends during his interview at 2022 Biotech Week Boston.

Four best practices for single-use supply chain success

Biopharma companies should consider these four best practices as they develop and manage their single-use supply chain.

CPhI Roundtable Discussion

Avantor’s Dr. Ger Brophy recently joined three industry colleagues for a pre-CPhI 2022 panel discussion hosted by The Medicine Maker magazine, discussing key biomanufacturing challenges.

Solving cost and supply challenges in biopharma downstream processing

Monoclonal antibodies (mAbs) are the dominant therapeutic modality in the biopharmaceutical industry, representing the largest sector of the market. As of 2022, more than 100 mAb therapies have been approved by the FDA – over twice as many as had been approved only 5 years ago.

Optimizing single-use manufacturing through associate training

How a new training room at Avantor Fluid Handling is ensuring the reliability and quality of your single-use systems

Processing challenges in realizing the future potential of mRNA vaccines and therapeutics

Jonathan Fura and Navjot Kaur provide insight into pain points in mRNA manufacturing and into the solutions that can evolve through the supplier-manufacturer relationship.

Viral Vectors: collaboration is key to fixing stability and other challenges

Opinion piece by Arvind Srivastata, Technical Fellow, describing the problems than can occur in viral vector production, and offering solutions based on a collaborative model that standardizes processes.

Approaches to alleviating subcutaneous pain at injection sites, a study

Arvind Srivastava, Technical Fellow; Ger Brophy, EVP, Biopharma Production Solutions and Meera Agarkhed, former Sr. Manager, Technology and Innovation discuss how formulations containing citrate compare to other buffers in reducing SC injection-site pain in a peer reviewed paper.

Industry perspective: much needed advances in biopharma chromatography

What is the purpose of chromatography in downstream processes of mAbs therapeutic manufacturing? And how does Avantor’s premium protein A chromatographic resin and single-use technologies to address the challenges of manufacturing a safe and effective final product? Learn more in this piece by Nandu Deorkar, Ph.D., M.B.A., Vice President R&D

Raw data – a 4.0 approach to materials offers process development benefits

Approaching raw material characterization with Biopharma 4.0 thinking in addition to robust collaboration between producers, vendors and end-users may improve biopharma manufacturing processes.

Tim Korwan, Director, New Product Introduction in Avantor’s single-use business spoke to BioSpectrum International in April 2021 about the integration of single-use technologies into fluid handling systems

A discussion about the challenges and benefits of having a well-designed and properly composed fluid handling system using single-use technology. Correct design and adoption of single-use technologies in fluid-handling systems helps streamline downstream bioprocessing operations.

Narayana Rao, Vice President, Biopharma, AMEA, spoke to BioSpectrum in May, 2021, about the ways Avantor contributes to the biopharma space

Since the beginning of the COVID-19 pandemic in 2020, Avantor has innovated and pivoted to help customers develop and scale-up the production novel vaccines. While the pandemic dominated the work of biopharma and life science companies, Avantor was also able to address multiple, ongoing global needs and continue to focus on the importance of strong supplier-manufacturer collaboration.

Interview with Narayana Rao, Vice President, Biopharma, AMEA in BioSpectrum Asia Edition (April 2021) on COVID-19 vaccine needs

Narayana Rao, Vice President, Biopharma, AMEA spoke to BioSpectrum in April 2021 about Avantor’s support of companies battling the global pandemic, and the potential of the AMEA region to meet COVID-19 vaccine needs.

Applying lessons from the semiconductor industry to biopharmaceutical production

Best practices in the semiconductor industry, including advanced materials analysis and characterization, can improve yields in biopharmaceutical production.

Formulation Development for AAV Viral Vectors

Adeno-associated virus (AAV) has emerged as a leading platform for gene delivery for treating various diseases due to its excellent safety profile and efficient transduction to various target tissues...

Raw Material Supply Chain Security for Cell and Gene Therapies

Cell therapies, including CAR-T and TCR-T, and gene therapies will offer transformative outcomes for challenging diseases.

Novel Resins for Downstream Process Intensification

The evolution of the monoclonal antibodies (mAbs) market, since approval of the first mAb more than 30 years ago, has dramatically changed patient care. Advances in technology as well as knowledge about antibody engineering have brought forth a wide range of targeted therapies to address previously unmet medical needs.

Removing bottlenecks in downstream processing purification

In producing monoclonal antibodies (mAbs), finding ways to remove bottlenecks and improve yields in downstream processing is a key focus area for biopharma manufacturers.

Bioprocessing in a Post COVID-19 World

COVID-19 has compressed bioprocessing timelines, leaving no room for uncertainty in the characterization of raw materials and contaminants.

Charting the rise of single-use

Single-use systems have come a long way. Timothy Korwan and Sean DeFusco, single-use experts from Avantor, discuss biopharma’s experience with the technology so far – and consider why it has become a popular choice for producing new drugs.

Alternative buffer management strategies to achieve downstream process improvements

There has been significant change across the biomanufacturing industry over the last couple of decades, as increased complexity of biologics and a growing focus on smaller patient populations have led to a greater need for cost control and process efficiency.

Vaccine manufacturing: COVID-19 and beyond

Scaling up cell & gene therapies from research and development to commercialization is creating a new set of challenges for manufacturers...

Single-use technology in cell and gene therapies

Scaling up cell & gene therapies from research and development to commercialization is creating a new set of challenges for manufacturers...

Improving mAb Manufacturing Productivity

It is common for biologics manufacturing processes to require hundreds of raw materials, ranging from media and media supplements, buffers, and salts to other process chemicals...

Advancing gene therapy by solving challenges in scale-up & manufacturing

Opportunities for advancements and challenges in manufacturing processes remain as the biopharmaceutical industry focuses on gene therapy.

Addressing Key Challenges Optimizing Downstream Bioprocessing

The term “optimize” is often applied to complex manufacturing, automation and business processes and implies that the most efficient function of all the elements of a process – technologies, sequences and procedures – has not been achieved...

Managing Single Use Supply Chain

With the rapid growth of single-use systems (SUS) for drug production, especially by drug manufacturers with multiple locations across the globe, there are many risks associated with underestimating the regulatory compliance, manufacturing and quality requirements of these systems...

Optimizing Upstream Bioprocessing

Despite significant advances made in recent years to increase biologic yields as well as the intensity and consistency of these processes, there is still the potential for innovation in this area in order to reach more efficient production of therapeutic proteins...

Considerations in Controlling Glycosylation

Continued expansion of the biosimilar marketplace has led to many commercial opportunities and technical challenges...

Challenges in Chromatography

Processing times can be reduced and yields increased by utilizing new hydrophobic interaction chromatography tools.

Opportunities and challenges in cell and gene therapy development

Q&A interview with Ger Brophy, Executive Vice President for Biopharma Production at Avantor.

Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world.